Psychiatry and Clinical Psychopharmacology
SHORT COMMUNICATION

Copper and Impulsivity in Ketamine Treatment for Treatment-Resistant Mood Disorders

1.

Department of Psychiatry, Medical University of Gdańsk School of Medicine, Gdańsk, Poland

Psychiatry and Clinical Psychopharmacology 2021; 31: 353-357
DOI: 10.5152/pcp.2021.21949
Read: 74 Downloads: 35 Published: 06 August 2021

Treatment-resistant mood disorders, including both major depressive disorder (MDD) and bipolar disorder (BD), are challenging to treat, as limited interventions exist. Ketamine exhibits an antidepressive effect in treatment-resistant depression. Abnormal copper levels might be associated with symptoms of depression. Impulsivity is related to measures of depression, both in MDD and in BD. The aim of this paper is to explore the associations between blood copper levels and impulsivity in patients who are treatment-resistant, in the course of treatment-resistant mood disorders. The paper does not support evidence for the link between copper concentrations and impulsivity outcomes in the course of shortterm ketamine treatment.

Cite this article as: Słupski J, Cubała W, Górska N, Słupska A, Gałuszko-Węgielnik M. Copper and impulsivity in ketamine treatment for treatment-resistant mood disorders. Psychiatr Clin Psychopharmacol. 2021;31(3):353-357.

Files
EISSN 2475-0581